A meeting is scheduled for October 1 that will bring together international experts from the Champalimaud Foundation in Lisbon, under the theme “Psychedelic Therapy: From Evidence to Equity.”
Over the course of the day, the discussion will focus on the challenges and opportunities of psychedelic-assisted therapy, a topic that has been high on the agenda for the European medical community, especially since Norway made ketamine-assisted treatment in a psychotherapy setting eligible for reimbursement at all public hospitals in August.
“This one-day event will bring together clinicians, researchers, patient advocates, policymakers, and ethics experts to explore the landscape of psychedelic-assisted care through the lens of the four pillars of medical ethics: beneficence, autonomy, non-maleficence, and justice,” according to the Champalimaud Foundation’s official website.
Safety, regulation, therapeutic practices, and future directions will be discussed throughout the day, with the aim of ensuring “equitable access to psychedelic-assisted care.”
The lineup includes more than a dozen speakers. Among them are Albino J. Oliveira-Maia, researcher and director of the Neuropsychiatry Unit at the Champalimaud Foundation; Alessandra Martini, advisor to the European Commission; and Carolina Seybert, clinical psychologist and researcher at the Neuropsychiatry Unit at the Champalimaud Foundation.
Also visiting Lisbon will be Neşe Devenot, an assistant professor at Johns Hopkins University; Tiago Machado, a clinical advisor at Infarmed; and Thomas Clausen, chief scientist at the European Union Agency for Drugs.
